Cancer Care Specialists of Illinois Welcomes Z. Jayson Yang, MD
(Decatur, IL) – Cancer Care Specialists of Illinois (CCSI) is pleased to announce the addition of Dr. Z. Jayson Yang, medical oncologist/hematologist, to its practice in February 2023. Dr. Yang primarily sees patients at the Cancer Care Center of Decatur and at CCSI’s clinic at Pana Community Hospital.
“Cancer Care is excited to welcome Dr. Yang to the Decatur community. Dr. Yang has joined our accomplished team of physicians and mid-level providers in the Cancer Care Center of Decatur where he is facilitating the continued delivery of excellent cancer care to patients in Decatur and many of its surrounding communities. CCSI and the Decatur community are fortunate to have such a compassionate, intelligent, and dedicated physician, colleague, and friend in the community.” – Justin D. Floyd, DO, FACOI, President of Cancer Care Specialists of Illinois.
Dr. Yang received his medical degree from the University College Dublin School of Medicine, National University of Ireland in 2010. He went on to complete postgraduate research in cancer therapeutics/prevention at Mayo Clinic in Rochester, Minnesota. Dr. Yang completed his Internal Medicine Residency at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. He subsequently completed a Fellowship in Medical Oncology at Ohio State University in Columbus, Ohio. Prior to joining CCSI, Dr. Yang was in clinical practice in Kansas City, Missouri.
“I am excited to be in central Illinois and appreciate the warm welcome from the Cancer Care team. By working with multiple stakeholders involved in cancer care, I look forward to contributing to this already well established program that has been providing quality care in central Illinois for almost 4 decades. I look forward to carrying on the tradition of providing advanced cancer care in a patient-centered, home town environment.” – Z. Jayson Yang, MD.
Dr. Yang is board certified in Internal Medicine and Medical Oncology. He is a member of the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
Dr. Yang has interests in a broad range of oncological disease groups that leverages on multi-disciplinary care. He is excited about ongoing progress in biomarker based therapies to include targeted agents and immunotherapy that are complementary to conventional chemotherapy approaches.